The mechanism of inhibitory effect of eicosapentaenoic acid on phagocytic activity and chemotaxis of human neutrophil granulocytes

S. Sipka, Indranil Dey, Csaba Buda, József Csongor, G. Szegedi, T. Farkas

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Free eicosapentaenoic acid (EPA) was found to inhibit dose dependently the chemiluminescence of human neutrophil granulocytes phagocytosing zymosan and their chemotaxis induced by C5a-containing zymosan-activated serum (ZAS) and platelet-activating factor. Rigidification of plasma membranes in the ZAS-treated cells could be observed by measuring the fluorescence anisotropy. The cells were labeled by 3-[p-(6-phenyl-1,3,5-hexatrienoil) phenyl] propionic acid, reporting plasma membrane for determination of membrane fluidity. In resting, nonstimulated neutrophils, EPA dose dependently increased the fluidity of plasma membrane. In zymosan-activated cells, however, after a short fluidization, the basic effect of EPA was a rigidification compared to very low fluorescence anisotropy values of activated control cells. This diminished fluidity, increased membrane stability of plasma membranes can be one of the reasons for the decreased functions (phagocytosis and chemotaxis) of human EPA-treated neutrophils.

Original languageEnglish
Pages (from-to)224-228
Number of pages5
JournalClinical Immunology and Immunopathology
Volume79
Issue number3
DOIs
Publication statusPublished - 1996

Fingerprint

Zymosan
Eicosapentaenoic Acid
Chemotaxis
Granulocytes
Human Activities
Neutrophils
Cell Membrane
Membrane Fluidity
Fluorescence Polarization
Phagocytosis
Platelet Activating Factor
Luminescence
Serum

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Pathology and Forensic Medicine

Cite this

The mechanism of inhibitory effect of eicosapentaenoic acid on phagocytic activity and chemotaxis of human neutrophil granulocytes. / Sipka, S.; Dey, Indranil; Buda, Csaba; Csongor, József; Szegedi, G.; Farkas, T.

In: Clinical Immunology and Immunopathology, Vol. 79, No. 3, 1996, p. 224-228.

Research output: Contribution to journalArticle

@article{2ac438409cf94200bfc73689170d7a24,
title = "The mechanism of inhibitory effect of eicosapentaenoic acid on phagocytic activity and chemotaxis of human neutrophil granulocytes",
abstract = "Free eicosapentaenoic acid (EPA) was found to inhibit dose dependently the chemiluminescence of human neutrophil granulocytes phagocytosing zymosan and their chemotaxis induced by C5a-containing zymosan-activated serum (ZAS) and platelet-activating factor. Rigidification of plasma membranes in the ZAS-treated cells could be observed by measuring the fluorescence anisotropy. The cells were labeled by 3-[p-(6-phenyl-1,3,5-hexatrienoil) phenyl] propionic acid, reporting plasma membrane for determination of membrane fluidity. In resting, nonstimulated neutrophils, EPA dose dependently increased the fluidity of plasma membrane. In zymosan-activated cells, however, after a short fluidization, the basic effect of EPA was a rigidification compared to very low fluorescence anisotropy values of activated control cells. This diminished fluidity, increased membrane stability of plasma membranes can be one of the reasons for the decreased functions (phagocytosis and chemotaxis) of human EPA-treated neutrophils.",
author = "S. Sipka and Indranil Dey and Csaba Buda and J{\'o}zsef Csongor and G. Szegedi and T. Farkas",
year = "1996",
doi = "10.1006/clin.1996.0072",
language = "English",
volume = "79",
pages = "224--228",
journal = "Clinical Immunology",
issn = "1521-6616",
publisher = "Academic Press Inc.",
number = "3",

}

TY - JOUR

T1 - The mechanism of inhibitory effect of eicosapentaenoic acid on phagocytic activity and chemotaxis of human neutrophil granulocytes

AU - Sipka, S.

AU - Dey, Indranil

AU - Buda, Csaba

AU - Csongor, József

AU - Szegedi, G.

AU - Farkas, T.

PY - 1996

Y1 - 1996

N2 - Free eicosapentaenoic acid (EPA) was found to inhibit dose dependently the chemiluminescence of human neutrophil granulocytes phagocytosing zymosan and their chemotaxis induced by C5a-containing zymosan-activated serum (ZAS) and platelet-activating factor. Rigidification of plasma membranes in the ZAS-treated cells could be observed by measuring the fluorescence anisotropy. The cells were labeled by 3-[p-(6-phenyl-1,3,5-hexatrienoil) phenyl] propionic acid, reporting plasma membrane for determination of membrane fluidity. In resting, nonstimulated neutrophils, EPA dose dependently increased the fluidity of plasma membrane. In zymosan-activated cells, however, after a short fluidization, the basic effect of EPA was a rigidification compared to very low fluorescence anisotropy values of activated control cells. This diminished fluidity, increased membrane stability of plasma membranes can be one of the reasons for the decreased functions (phagocytosis and chemotaxis) of human EPA-treated neutrophils.

AB - Free eicosapentaenoic acid (EPA) was found to inhibit dose dependently the chemiluminescence of human neutrophil granulocytes phagocytosing zymosan and their chemotaxis induced by C5a-containing zymosan-activated serum (ZAS) and platelet-activating factor. Rigidification of plasma membranes in the ZAS-treated cells could be observed by measuring the fluorescence anisotropy. The cells were labeled by 3-[p-(6-phenyl-1,3,5-hexatrienoil) phenyl] propionic acid, reporting plasma membrane for determination of membrane fluidity. In resting, nonstimulated neutrophils, EPA dose dependently increased the fluidity of plasma membrane. In zymosan-activated cells, however, after a short fluidization, the basic effect of EPA was a rigidification compared to very low fluorescence anisotropy values of activated control cells. This diminished fluidity, increased membrane stability of plasma membranes can be one of the reasons for the decreased functions (phagocytosis and chemotaxis) of human EPA-treated neutrophils.

UR - http://www.scopus.com/inward/record.url?scp=0029996698&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029996698&partnerID=8YFLogxK

U2 - 10.1006/clin.1996.0072

DO - 10.1006/clin.1996.0072

M3 - Article

C2 - 8635279

AN - SCOPUS:0029996698

VL - 79

SP - 224

EP - 228

JO - Clinical Immunology

JF - Clinical Immunology

SN - 1521-6616

IS - 3

ER -